In vitro characterization of commercial factor VIII concentrates: Long-term follow-up

1984 ◽  
Vol 49 (1) ◽  
pp. 53-59 ◽  
Author(s):  
C. Miyashita ◽  
P. Hellstern ◽  
M. K�hler ◽  
G. Blohn ◽  
E. Wenzel
Keyword(s):  
Factor Viii ◽  
In Vitro Characterization ◽  
Long Term Follow Up ◽  
Factor Viii Concentrates

Post-Operative Dysphagia in Anterior Cervical Discectomy and Fusion

2021 ◽  
pp. 000348942110155
Author(s):  
Leonard Haller ◽  
Khush Mehul Kharidia ◽  
Caitlin Bertelsen ◽  
Jeffrey Wang ◽  
Karla O’Dell
Keyword(s):  
Risk Factors ◽  
Medical Records ◽  
Assessment Tool ◽  
Demographic Data ◽  
Anterior Cervical Discectomy ◽  
Cervical Discectomy ◽  
Long Term Follow Up

Objective: We sought to identify risk factors associated with long-term dysphagia, characterize changes in dysphagia over time, and evaluate the incidence of otolaryngology referrals for patients with long-term dysphagia following anterior cervical discectomy with fusion (ACDF). Methods: About 56 patients who underwent ACDF between May 2017 to February 2019 were included in the study. All patients were assessed for dysphagia using the Eating Assessment Tool (EAT-10) survey preoperatively and late postoperatively (≥1 year). Additionally, 28 patients were assessed for dysphagia early postoperatively (2 weeks—3 months). Demographic data, medical comorbidities, intraoperative details, and post-operative otolaryngology referral rates were collected from electronic medical records. Results: Of the 56 patients enrolled, 21 patients (38%) had EAT-10 scores of 3 or more at long-term follow-up. None of the demographics, comorbidities, or surgical factors assessed were associated with long-term dysphagia. Patients who reported no long-term dysphagia had a mean EAT-10 score of 6.9 early postoperatively, while patients with long-term symptoms had a mean score of 18.1 ( P = .006). Of the 21 patients who reported persistent dysphagia symptoms, 3 (14%) received dysphagia testing or otolaryngology referrals post-operatively. Conclusion: Dysphagia is a notable side effect of ACDF surgery, but there are no significant demographics, comorbidities, or surgical risk factors that predict long-term dysphagia. Early postoperative characterization of dysphagia using the EAT-10 questionnaire can help predict long-term symptoms. There is inadequate screening and otolaryngology follow-up for patients with post-ACDF dysphagia.

Primary Pulmonary Pleomorphic Adenoma

2003 ◽  
Vol 127 (5) ◽  
pp. 621-622
Author(s):  
Keng Leong Ang ◽  
Venkata Ramana Dhannapuneni ◽  
William Ellis Morgan ◽  
Irshad Nabi Soomro
Keyword(s):  
Pleomorphic Adenoma ◽  
Regulatory Gene ◽  
Proliferation Index ◽  
Complete Excision ◽  
Long Term Follow Up ◽  
Uncommon Condition ◽  
P16 Ink4a

Abstract Primary pleomorphic adenoma of the lung is an uncommon condition. We present a case of primary pulmonary pleomorphic adenoma and its immunohistologic features. The presence of immunoreactivity to both anticytokeratin and antivimentin antibodies for its epithelial components is suggestive of a primary pulmonary lesion. Its high proliferation index and its immunoreactivity to tumor regulatory gene p16(INK4A) are features that, to our knowledge, have not been reported previously. They may have a role in the frequent recurrence of these tumors many years after their apparently complete excision. Detailed genetic investigation and long-term follow-up of this rare tumor will aid in the characterization of its biologic profile.

scholarly journals Long-term follow up of feline leukemia virus infection and characterization of viral RNA loads using molecular methods in tissues of cats with different infection outcomes

2015 ◽  
Vol 197 ◽  
pp. 137-150 ◽  
Author(s):  
A. Katrin Helfer-Hungerbuehler ◽  
Stefan Widmer ◽  
Yvonne Kessler ◽  
Barbara Riond ◽  
Felicitas S. Boretti ◽  
...  
Keyword(s):  
Virus Infection ◽  
Leukemia Virus ◽  
Molecular Methods ◽  
Viral Rna ◽  
Feline Leukemia Virus ◽  
Long Term Follow Up

scholarly journals Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review

BJGP Open ◽  
2020 ◽  
Vol 4 (2) ◽  
pp. bjgpopen20X101069 ◽  
Author(s):  
Kome Gbinigie ◽  
Kerstin Frie
Keyword(s):  
Clinical Trials ◽  
Relevant Literature ◽  
Safety Data ◽  
World Health ◽  
Rapid Review ◽  
Current Evidence ◽  
Long Term Follow Up

BackgroundOn the 11 March 2020, the World Health Organization (WHO) declared that COVID-19 was a pandemic. To date, there are no medical treatments for COVID-19 with proven effectiveness. Novel treatments and/or vaccines will take time to be developed and distributed to patients. In light of this, there has been growing interest in the use of existing medications, such as chloroquine (CQ) and hydroxychloroquine (HCQ), as potential treatments of this disease.AimTo establish the current evidence for the effectiveness of CQ and HCQ in treating COVID-19.Design & settingA rapid review of the literature was conducted.MethodElectronic searches in PubMed and Google Scholar were conducted on 21 March 2020. A further search was conducted in Google for relevant literature on 28 March 2020.ResultsThere is limited evidence of in vitro activity of CQ/HCQ against SARS-CoV-2. A number of in vivo clinical trials are underway. The empirical data available from two of these trials reveal conflicting results. Both trials are characterised by small numbers of participants (n = 30 and n = 36) and suffer methodological limitations. No medium or long-term follow-up data is available.ConclusionAt present, there is insufficient evidence to determine whether CQ/HCQ are safe and effective treatments for COVID-19. High quality, adequately powered randomised clinical trials in primary and secondary care settings are urgently required to guide policymakers and clinicians. These studies should report medium- and long-term follow-up results, and safety data.

Rituximab for the Treatment of High Titer Acquired Factor VIII Inhibitor with Long Term Follow up

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4524-4524
Author(s):  
Shylendra B Sreenivasappa ◽  
Margaret Clare Telfer
Keyword(s):  
Factor Viii ◽  
High Titer ◽  
Factor Viii Inhibitor ◽  
Sustained Remission ◽  
Related Complication ◽  
Significant Treatment ◽  
Patients Âgés ◽  
Long Term Follow Up

Abstract Acquired factor VIII inhibitors are auto antibodies directed against factor VIII (FVIII) and have a reported incidence of 0.2–1.0 per million individuals per year. It is a rare cause of serious bleeding associated with high mortality. Individuals with high titer antibodies (> 100 Bethesda units (BU)), often have difficulty achieving a complete sustained remission although different strategies have been advocated for these patients. Rituximab has been demonstrated to show efficacy in patients with acquired hemophilia. In this study we retrospectively studied three patients with high titer acquired FVIII inhibitors with long term follow up. Two of the patients were resistant to steroids and Intravenous Immunoglobulin, one patient had received steroids and Cyclophosphamide prior to rituximab therapy. Patients ages were 36, 45 and 48 years, two were women and one male. One of the women has a h/o pregnancy about 8 months ago and other two were thought to have idiopathic inhibitors. The patient’s inhibitor titers ranged from 124–800 BU at the time of treatment with Rituximab. All received 4 weekly infusion of rituximab at 375mg/m2. No significant treatment related complication was noted. One patient did not respond to treatment. Two patients had a decline in inhibitor titers. One patient had a gradual drop in titer from 124 BU to 0.00 BU over 18 months. The other responder had a drop in titer from 800 BU to 41 BU in 16 months and then relapsed with significant bleeding and anti factor 8 titers of 700 BU and was retreated with rituximab and had a gradual drop in inhibitor titers to 50 BU over 8 months. The two patients have been followed for 28 and 30 months respectively. The non responder continues to have high tires of antibodies and has been followed for 25 months. We conclude that in patients with high titer of acquired inhibitors rituximab alone may produce a drop in inhibitor titer but is not sufficient to achieve a complete response. Rituximab in combination with other therapies or novel agents may provide better results,

Characterization of the “one-pad patient” at long-term follow-up after radical prostatectomy

2017 ◽  
Vol 16 (3) ◽  
pp. e1890
Author(s):  
B. Löppenberg ◽  
G. Müller ◽  
P. Bach ◽  
C. Von Bodman ◽  
M. Brock ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
Long Term Follow Up ◽  
The One

scholarly journals Development and in vitro characterization of poly(lactide-co-glycolide) microspheres loaded with an antibacterial natural drug for the treatment of long-term bacterial infections

2016 ◽  
Vol Volume 10 ◽  
pp. 2823-2832 ◽  
Author(s):  
Stefanie Krajewski ◽  
Jochen Reinbold ◽  
Teresa Hierlemann ◽  
Helena Hinkel ◽  
Ingrid Müller ◽  
...  
Keyword(s):  
Bacterial Infections ◽  
In Vitro Characterization

scholarly journals MP82-10 CHARACTERIZATION OF THE “ONE-PAD PATIENT” AT LONG-TERM FOLLOW-UP AFTER RADICAL PROSTATECTOMY

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Björn Löppenberg ◽  
Guido Müller ◽  
Peter Bach ◽  
Christian von Bodman ◽  
Marko Brock ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
Long Term Follow Up ◽  
The One

Risk Factors and Long-term Follow-up of Patients with the Immune Type of Heparin-Induced Thrombocytopenia

2002 ◽  
Vol 8 (4) ◽  
pp. 347-352 ◽  
Author(s):  
Edelgard Lindhoff-Last ◽  
Britta Wenning ◽  
Martina Stein ◽  
Frank Gerdsen ◽  
Rupert Bauersachs ◽  
...  
Keyword(s):  
Risk Factors ◽  
Factor Viii ◽  
Protein C ◽  
Protein S ◽  
Factor Xii ◽  
Factor V ◽  
Heparin Induced Thrombocytopenia ◽  
Long Term Follow Up

Dispositional risk factors for developing the immune-type of heparin-induced thrombocytopenia (HIT) are yet unclear. This article presents a long-term follow-up of patients with HIT to define possible risk factors that may increase the risk of HIT. The clinical course of acute HIT was analyzed retrospectively in 52 patients with HIT. Thirteen patients died;8 due to HIT. A follow-up investigation was performed in 28 of the remaining 39 patients 29 ± 12 months after the onset of HIT, including genotyping for the factor V G1691A- and the prothrombin G20210A-mutation, measurement of antithrombin, protein C, protein S, factor VIII, and factor XII activity as well as the concentration of antiphospholipid antibodies. The results were compared to an age- and sex-matched control group. New thromboembolic events and re-exposure to heparin were also documented. No difference between patients and controls was observed concerning the factor V Leiden mutation, the prothrombin mutation, factor XII, antithrombin, protein S, or protein C deficiency and antiphospholipid antibodies. Increased factor VIII activity was found in 16 of 21 HIT patients compared to 4 of 21 controls (p=0.0005). New thromboembolic events developed in 5 patients within 9 months after HIT. One patient had been re-exposed to heparin 9 months after acute HIT without any complications. Increased factor VIII activity was frequently observed in patients in whom HIT developed. Thromboembolic complications within the first months after onset of HIT occurred often.

Sign in / Sign up

Export Citation Format

Share Document